Catalent/CTLT
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Catalent
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Ticker
CTLT
Sector
Healthcare
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Somerset, United States
Employees
17,800
Website
www.catalent.com
Catalent Metrics
BasicAdvanced
$10B
Market cap
-
P/E ratio
-$6.47
EPS
1.20
Beta
-
Dividend rate
Price and volume
Market cap
$10B
Beta
1.2
Financial strength
Current ratio
2.505
Quick ratio
1.03
Long term debt to equity
136.61
Total debt to equity
138.189
Interest coverage (TTM)
-0.32%
Management effectiveness
Return on assets (TTM)
-0.48%
Return on equity (TTM)
-28.29%
Valuation
Price to revenue (TTM)
2.47
Price to book
2.82
Price to tangible book (TTM)
25.61
Price to free cash flow (TTM)
-83.04
Growth
Revenue change (TTM)
-8.01%
Earnings per share change (TTM)
-5,615.29%
3-year revenue growth
3.24%
3-year earnings per share growth
29.83%
What the Analysts think about Catalent
Analyst Ratings
Majority rating from 11 analysts.
Catalent Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$1.1B
4.88%
Net income
-$101M
-50.97%
Profit margin
-9.40%
-53.26%
Catalent Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$0.09
-$0.10
-$0.24
-$0.06
-
Expected
$0.10
-$0.14
-$0.02
$0.21
$0.53
Surprise
-13.04%
-26.55%
1,055.57%
-128.72%
-
Catalent News
AllArticlesVideos
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
GlobeNewsWire·2 months ago
US FTC seeks more information on Novo Nordisk parent-Catalent deal
Reuters·2 months ago
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Catalent stock?
Catalent (CTLT) has a market cap of $10B as of July 03, 2024.
What is the P/E ratio for Catalent stock?
The price to earnings (P/E) ratio for Catalent (CTLT) stock is 0 as of July 03, 2024.
Does Catalent stock pay dividends?
No, Catalent (CTLT) stock does not pay dividends to its shareholders as of July 03, 2024.
When is the next Catalent dividend payment date?
Catalent (CTLT) stock does not pay dividends to its shareholders.
What is the beta indicator for Catalent?
Catalent (CTLT) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Catalent stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.